Report Detail
Global Liver Fibrosis Drug Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
- RnM3580066 |
- 08 July, 2019 |
- Global |
- 122 Pages |
- GIR (Global Info Research) |
- Pharma & Healthcare
Liver fibrosis is the scarring process that represents the liver’s response to injury. In the same way as skin and other organs heal wounds through deposition of collagen and other matrix constituents so the liver repairs injury through the deposition of new collagen.
Scope of the Report:
The classification of Liver Fibrosis Drug includes nucleoside, interferon and others, and the proportion of nucleoside type in 2018 is about 45.37%, and the proportion keeps stable trend from 2014 to 2025.Liver fibrosis drug is widely used for Hepatitis, Liver Fibrosis and Other. The most proportion of Interferon is used for hepatitis, and the proportion in 2018 is 68.37%.
North America is the largest consumption place, with a consumption market share nearly 47.09% in 2018. Following North America, Europe is the second largest consumption place with the consumption market share of 25.14%.
Market competition is intense. Gilead, Biogen Idec, Merck KGaA, Bristol-Myers Squibb Company, Roche, Merck & Co., Inc and Tri-Prime are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
The worldwide market for Liver Fibrosis Drug is expected to grow at a CAGR of roughly -1.7% over the next five years, will reach 13530 million US$ in 2024, from 14710 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Liver Fibrosis Drug in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Gilead
Biogen Idec
Merck KGaA
Bristol-Myers Squibb Company
Roche
Merck & Co.
Tri-Prime
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Nucleoside
Interferon
Other
Market Segment by Applications, can be divided into
Hepatitis
Liver Fibrosis
Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Liver Fibrosis Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Liver Fibrosis Drug, with price, sales, revenue and global market share of Liver Fibrosis Drug in 2017 and 2018.
Chapter 3, the Liver Fibrosis Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Liver Fibrosis Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Liver Fibrosis Drug market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Liver Fibrosis Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
- 1.1 Liver Fibrosis Drug Introduction
- 1.2 Market Analysis by Type
- 1.2.1 Nucleoside
- 1.2.2 Interferon
- 1.2.3 Other
- 1.3 Market Analysis by Applications
- 1.3.1 Hepatitis
- 1.3.2 Liver Fibrosis
- 1.3.3 Other
- 1.4 Market Analysis by Regions
- 1.4.1 North America (United States, Canada and Mexico)
- 1.4.1.1 United States Market States and Outlook (2014-2024)
- 1.4.1.2 Canada Market States and Outlook (2014-2024)
- 1.4.1.3 Mexico Market States and Outlook (2014-2024)
- 1.4.2 Europe (Germany, France, UK, Russia and Italy)
- 1.4.2.1 Germany Market States and Outlook (2014-2024)
- 1.4.2.2 France Market States and Outlook (2014-2024)
- 1.4.2.3 UK Market States and Outlook (2014-2024)
- 1.4.2.4 Russia Market States and Outlook (2014-2024)
- 1.4.2.5 Italy Market States and Outlook (2014-2024)
- 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- 1.4.3.1 China Market States and Outlook (2014-2024)
- 1.4.3.2 Japan Market States and Outlook (2014-2024)
- 1.4.3.3 Korea Market States and Outlook (2014-2024)
- 1.4.3.4 India Market States and Outlook (2014-2024)
- 1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
- 1.4.4 South America, Middle East and Africa
- 1.4.4.1 Brazil Market States and Outlook (2014-2024)
- 1.4.4.2 Egypt Market States and Outlook (2014-2024)
- 1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
- 1.4.4.4 South Africa Market States and Outlook (2014-2024)
- 1.4.4.5 Turkey Market States and Outlook (2014-2024)
- 1.4.1 North America (United States, Canada and Mexico)
- 1.5 Market Dynamics
- 1.5.1 Market Opportunities
- 1.5.2 Market Risk
- 1.5.3 Market Driving Force
2 Manufacturers Profiles
- 2.1 Gilead
- 2.1.1 Business Overview
- 2.1.2 Liver Fibrosis Drug Type and Applications
- 2.1.2.1 Product A
- 2.1.2.2 Product B
- 2.1.3 Gilead Liver Fibrosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
- 2.2 Biogen Idec
- 2.2.1 Business Overview
- 2.2.2 Liver Fibrosis Drug Type and Applications
- 2.2.2.1 Product A
- 2.2.2.2 Product B
- 2.2.3 Biogen Idec Liver Fibrosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
- 2.3 Merck KGaA
- 2.3.1 Business Overview
- 2.3.2 Liver Fibrosis Drug Type and Applications
- 2.3.2.1 Product A
- 2.3.2.2 Product B
- 2.3.3 Merck KGaA Liver Fibrosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
- 2.4 Bristol-Myers Squibb Company
- 2.4.1 Business Overview
- 2.4.2 Liver Fibrosis Drug Type and Applications
- 2.4.2.1 Product A
- 2.4.2.2 Product B
- 2.4.3 Bristol-Myers Squibb Company Liver Fibrosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
- 2.5 Roche
- 2.5.1 Business Overview
- 2.5.2 Liver Fibrosis Drug Type and Applications
- 2.5.2.1 Product A
- 2.5.2.2 Product B
- 2.5.3 Roche Liver Fibrosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
- 2.6 Merck & Co.
- 2.6.1 Business Overview
- 2.6.2 Liver Fibrosis Drug Type and Applications
- 2.6.2.1 Product A
- 2.6.2.2 Product B
- 2.6.3 Merck & Co. Liver Fibrosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
- 2.7 Tri-Prime
- 2.7.1 Business Overview
- 2.7.2 Liver Fibrosis Drug Type and Applications
- 2.7.2.1 Product A
- 2.7.2.2 Product B
- 2.7.3 Tri-Prime Liver Fibrosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
3 Global Liver Fibrosis Drug Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)
- 3.1 Global Liver Fibrosis Drug Sales and Market Share by Manufacturer (2017-2018)
- 3.2 Global Liver Fibrosis Drug Revenue and Market Share by Manufacturer (2017-2018)
- 3.3 Market Concentration Rate
- 3.3.1 Top 3 Liver Fibrosis Drug Manufacturer Market Share in 2018
- 3.3.2 Top 6 Liver Fibrosis Drug Manufacturer Market Share in 2018
- 3.4 Market Competition Trend
4 Global Liver Fibrosis Drug Market Analysis by Regions
- 4.1 Global Liver Fibrosis Drug Sales, Revenue and Market Share by Regions
- 4.1.1 Global Liver Fibrosis Drug Sales and Market Share by Regions (2014-2019)
- 4.1.2 Global Liver Fibrosis Drug Revenue and Market Share by Regions (2014-2019)
- 4.2 North America Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
- 4.3 Europe Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
- 4.4 Asia-Pacific Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
- 4.5 South America Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
- 4.6 Middle East and Africa Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
5 North America Liver Fibrosis Drug by Country
- 5.1 North America Liver Fibrosis Drug Sales, Revenue and Market Share by Country
- 5.1.1 North America Liver Fibrosis Drug Sales and Market Share by Country (2014-2019)
- 5.1.2 North America Liver Fibrosis Drug Revenue and Market Share by Country (2014-2019)
- 5.2 United States Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
- 5.3 Canada Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
- 5.4 Mexico Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
6 Europe Liver Fibrosis Drug by Country
- 6.1 Europe Liver Fibrosis Drug Sales, Revenue and Market Share by Country
- 6.1.1 Europe Liver Fibrosis Drug Sales and Market Share by Country (2014-2019)
- 6.1.2 Europe Liver Fibrosis Drug Revenue and Market Share by Country (2014-2019)
- 6.2 Germany Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
- 6.3 UK Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
- 6.4 France Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
- 6.5 Russia Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
- 6.6 Italy Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
7 Asia-Pacific Liver Fibrosis Drug by Country
- 7.1 Asia-Pacific Liver Fibrosis Drug Sales, Revenue and Market Share by Country
- 7.1.1 Asia-Pacific Liver Fibrosis Drug Sales and Market Share by Country (2014-2019)
- 7.1.2 Asia-Pacific Liver Fibrosis Drug Revenue and Market Share by Country (2014-2019)
- 7.2 China Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
- 7.3 Japan Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
- 7.4 Korea Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
- 7.5 India Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
- 7.6 Southeast Asia Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
8 South America Liver Fibrosis Drug by Country
- 8.1 South America Liver Fibrosis Drug Sales, Revenue and Market Share by Country
- 8.1.1 South America Liver Fibrosis Drug Sales and Market Share by Country (2014-2019)
- 8.1.2 South America Liver Fibrosis Drug Revenue and Market Share by Country (2014-2019)
- 8.2 Brazil Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
- 8.3 Argentina Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
- 8.4 Colombia Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
9 Middle East and Africa Liver Fibrosis Drug by Countries
- 9.1 Middle East and Africa Liver Fibrosis Drug Sales, Revenue and Market Share by Country
- 9.1.1 Middle East and Africa Liver Fibrosis Drug Sales and Market Share by Country (2014-2019)
- 9.1.2 Middle East and Africa Liver Fibrosis Drug Revenue and Market Share by Country (2014-2019)
- 9.2 Saudi Arabia Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
- 9.3 Turkey Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
- 9.4 Egypt Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
- 9.5 Nigeria Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
- 9.6 South Africa Liver Fibrosis Drug Sales and Growth Rate (2014-2019)
10 Global Liver Fibrosis Drug Market Segment by Type
- 10.1 Global Liver Fibrosis Drug Sales, Revenue and Market Share by Type (2014-2019)
- 10.1.1 Global Liver Fibrosis Drug Sales and Market Share by Type (2014-2019)
- 10.1.2 Global Liver Fibrosis Drug Revenue and Market Share by Type (2014-2019)
- 10.2 Nucleoside Sales Growth and Price
- 10.2.1 Global Nucleoside Sales Growth (2014-2019)
- 10.2.2 Global Nucleoside Price (2014-2019)
- 10.3 Interferon Sales Growth and Price
- 10.3.1 Global Interferon Sales Growth (2014-2019)
- 10.3.2 Global Interferon Price (2014-2019)
- 10.4 Other Sales Growth and Price
- 10.4.1 Global Other Sales Growth (2014-2019)
- 10.4.2 Global Other Price (2014-2019)
11 Global Liver Fibrosis Drug Market Segment by Application
- 11.1 Global Liver Fibrosis Drug Sales Market Share by Application (2014-2019)
- 11.2 Hepatitis Sales Growth (2014-2019)
- 11.3 Liver Fibrosis Sales Growth (2014-2019)
- 11.4 Other Sales Growth (2014-2019)
12 Liver Fibrosis Drug Market Forecast (2019-2024)
- 12.1 Global Liver Fibrosis Drug Sales, Revenue and Growth Rate (2019-2024)
- 12.2 Liver Fibrosis Drug Market Forecast by Regions (2019-2024)
- 12.2.1 North America Liver Fibrosis Drug Market Forecast (2019-2024)
- 12.2.2 Europe Liver Fibrosis Drug Market Forecast (2019-2024)
- 12.2.3 Asia-Pacific Liver Fibrosis Drug Market Forecast (2019-2024)
- 12.2.4 South America Liver Fibrosis Drug Market Forecast (2019-2024)
- 12.2.5 Middle East and Africa Liver Fibrosis Drug Market Forecast (2019-2024)
- 12.3 Liver Fibrosis Drug Market Forecast by Type (2019-2024)
- 12.3.1 Global Liver Fibrosis Drug Sales Forecast by Type (2019-2024)
- 12.3.2 Global Liver Fibrosis Drug Market Share Forecast by Type (2019-2024)
- 12.4 Liver Fibrosis Drug Market Forecast by Application (2019-2024)
- 12.4.1 Global Liver Fibrosis Drug Sales Forecast by Application (2019-2024)
- 12.4.2 Global Liver Fibrosis Drug Market Share Forecast by Application (2019-2024)
13 Sales Channel, Distributors, Traders and Dealers
- 13.1 Sales Channel
- 13.1.1 Direct Marketing
- 13.1.2 Indirect Marketing
- 13.1.3 Marketing Channel Future Trend
- 13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
- 15.1 Methodology
Summary:
Get latest Market Research Reports on Liver Fibrosis Drug. Industry analysis & Market Report on Liver Fibrosis Drug is a syndicated market report, published as Global Liver Fibrosis Drug Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024. It is complete Research Study and Industry Analysis of Liver Fibrosis Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
